Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy

Y Lu, YT Chan, HY Tan, S Li, N Wang, Y Feng - Molecular cancer, 2020 - Springer
Epigenetics is dynamic and heritable modifications to the genome that occur independently
of DNA sequence. It requires interactions cohesively with various enzymes and other …

Combining epigenetic drugs with other therapies for solid tumours—past lessons and future promise

D Morel, D Jeffery, S Aspeslagh, G Almouzni… - Nature Reviews …, 2020 - nature.com
Epigenetic dysregulation has long been recognized as a key factor contributing to
tumorigenesis and tumour maintenance that can influence all of the recognized hallmarks of …

Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends

K Nepali, JP Liou - Journal of Biomedical Science, 2021 - Springer
Epigenetic drug discovery field has evidenced significant advancement in the recent times.
A plethora of small molecule inhibitors have progressed to clinical stage investigations and …

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents

K Ververis, A Hiong, TC Karagiannis… - Biologics: Targets and …, 2013 - Taylor & Francis
Histone deacetylase (HDAC) inhibitors are an emerging class of therapeutics with potential
as anticancer drugs. The rationale for developing HDAC inhibitors (and other chromatin …

Epigenetics in cancer: targeting chromatin modifications

L Ellis, PW Atadja, RW Johnstone - Molecular cancer therapeutics, 2009 - AACR
Posttranslational modifications to histones affect chromatin structure and function resulting in
altered gene expression and changes in cell behavior. Aberrant gene expression and …

Epigenetic treatment of solid tumours: a review of clinical trials

C Nervi, E De Marinis, G Codacci-Pisanelli - Clinical epigenetics, 2015 - Springer
Epigenetic treatment has been approved by regulatory agencies for haematological
malignancies. The success observed in cutaneous lymphomas represents a proof of …

Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection

T Roger, J Lugrin, D Le Roy, G Goy… - Blood, The Journal …, 2011 - ashpublications.org
Regulated by histone acetyltransferases and deacetylases (HDACs), histone acetylation is a
key epigenetic mechanism controlling chromatin structure, DNA accessibility, and gene …

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

J Tan, S Cang, Y Ma, RL Petrillo, D Liu - Journal of hematology & oncology, 2010 - Springer
Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and
activities of transcriptional factors involved in both cancer initiation and progression through …

Augmenting antitumor immune responses with epigenetic modifying agents

E Héninger, TEG Krueger, JM Lang - Frontiers in immunology, 2015 - frontiersin.org
Epigenetic silencing of immune-related genes is a striking feature of the cancer genome that
occurs in the process of tumorigenesis. This phenomena impacts antigen processing and …

Belinostat: first global approval

RM Poole - Drugs, 2014 - Springer
Abstract Belinostat [Beleodaq®(US)], a small-molecule hydroxamate-type inhibitor of class I,
II and IV histone deacetylase (HDAC) enzymes, has been developed by TopoTarget and …